Enhancing clinical trial development for pediatric kidney diseases

H. William Schnaper, Joseph T. Flynn, Coleman Gross, Anne B. Cropp, Bastian Dehmel, Leah B. Patel, Larry A. Greenbaum, Elisabeth Houtsmuller, Frederick J. Kaskel, Marva Moxey-Mims, Karen Nowak, Douglas Silverstein, Aliza Thompson, Lynne Yao, Edress Darsey, William E. Smoyer

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The conduct of clinical trials in small pediatric subspecialties such as pediatric nephrology is hampered by both clinical demands on the pediatric nephrologist and the small number of appropriate patients available for such studies. The American Society of Pediatric Nephrology Therapeutics Development Committee (TDC) was established to (1) identify the various stakeholders with interests and/or expertise related to clinical trials in children with kidney disease and (2) develop more effective partnerships among all parties regarding strategies for successful clinical trial development and execution. This article discusses the rationale, structure, and function of the TDC, the status of progress toward its goals, and the insights gained to date that may be useful for other subspecialties that face similar challenges.

Original languageEnglish (US)
Pages (from-to)727-732
Number of pages6
JournalPediatric Research
Volume82
Issue number5
DOIs
StatePublished - Nov 1 2017

Fingerprint

Kidney Diseases
Pharmacy and Therapeutics Committee
Clinical Trials
Pediatrics
Nephrology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Schnaper, H. W., Flynn, J. T., Gross, C., Cropp, A. B., Dehmel, B., Patel, L. B., ... Smoyer, W. E. (2017). Enhancing clinical trial development for pediatric kidney diseases. Pediatric Research, 82(5), 727-732. https://doi.org/10.1038/pr.2017.180

Enhancing clinical trial development for pediatric kidney diseases. / Schnaper, H. William; Flynn, Joseph T.; Gross, Coleman; Cropp, Anne B.; Dehmel, Bastian; Patel, Leah B.; Greenbaum, Larry A.; Houtsmuller, Elisabeth; Kaskel, Frederick J.; Moxey-Mims, Marva; Nowak, Karen; Silverstein, Douglas; Thompson, Aliza; Yao, Lynne; Darsey, Edress; Smoyer, William E.

In: Pediatric Research, Vol. 82, No. 5, 01.11.2017, p. 727-732.

Research output: Contribution to journalReview article

Schnaper, HW, Flynn, JT, Gross, C, Cropp, AB, Dehmel, B, Patel, LB, Greenbaum, LA, Houtsmuller, E, Kaskel, FJ, Moxey-Mims, M, Nowak, K, Silverstein, D, Thompson, A, Yao, L, Darsey, E & Smoyer, WE 2017, 'Enhancing clinical trial development for pediatric kidney diseases', Pediatric Research, vol. 82, no. 5, pp. 727-732. https://doi.org/10.1038/pr.2017.180
Schnaper HW, Flynn JT, Gross C, Cropp AB, Dehmel B, Patel LB et al. Enhancing clinical trial development for pediatric kidney diseases. Pediatric Research. 2017 Nov 1;82(5):727-732. https://doi.org/10.1038/pr.2017.180
Schnaper, H. William ; Flynn, Joseph T. ; Gross, Coleman ; Cropp, Anne B. ; Dehmel, Bastian ; Patel, Leah B. ; Greenbaum, Larry A. ; Houtsmuller, Elisabeth ; Kaskel, Frederick J. ; Moxey-Mims, Marva ; Nowak, Karen ; Silverstein, Douglas ; Thompson, Aliza ; Yao, Lynne ; Darsey, Edress ; Smoyer, William E. / Enhancing clinical trial development for pediatric kidney diseases. In: Pediatric Research. 2017 ; Vol. 82, No. 5. pp. 727-732.
@article{f439a0dd20cb4ed5b103c9758d649b73,
title = "Enhancing clinical trial development for pediatric kidney diseases",
abstract = "The conduct of clinical trials in small pediatric subspecialties such as pediatric nephrology is hampered by both clinical demands on the pediatric nephrologist and the small number of appropriate patients available for such studies. The American Society of Pediatric Nephrology Therapeutics Development Committee (TDC) was established to (1) identify the various stakeholders with interests and/or expertise related to clinical trials in children with kidney disease and (2) develop more effective partnerships among all parties regarding strategies for successful clinical trial development and execution. This article discusses the rationale, structure, and function of the TDC, the status of progress toward its goals, and the insights gained to date that may be useful for other subspecialties that face similar challenges.",
author = "Schnaper, {H. William} and Flynn, {Joseph T.} and Coleman Gross and Cropp, {Anne B.} and Bastian Dehmel and Patel, {Leah B.} and Greenbaum, {Larry A.} and Elisabeth Houtsmuller and Kaskel, {Frederick J.} and Marva Moxey-Mims and Karen Nowak and Douglas Silverstein and Aliza Thompson and Lynne Yao and Edress Darsey and Smoyer, {William E.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1038/pr.2017.180",
language = "English (US)",
volume = "82",
pages = "727--732",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Enhancing clinical trial development for pediatric kidney diseases

AU - Schnaper, H. William

AU - Flynn, Joseph T.

AU - Gross, Coleman

AU - Cropp, Anne B.

AU - Dehmel, Bastian

AU - Patel, Leah B.

AU - Greenbaum, Larry A.

AU - Houtsmuller, Elisabeth

AU - Kaskel, Frederick J.

AU - Moxey-Mims, Marva

AU - Nowak, Karen

AU - Silverstein, Douglas

AU - Thompson, Aliza

AU - Yao, Lynne

AU - Darsey, Edress

AU - Smoyer, William E.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The conduct of clinical trials in small pediatric subspecialties such as pediatric nephrology is hampered by both clinical demands on the pediatric nephrologist and the small number of appropriate patients available for such studies. The American Society of Pediatric Nephrology Therapeutics Development Committee (TDC) was established to (1) identify the various stakeholders with interests and/or expertise related to clinical trials in children with kidney disease and (2) develop more effective partnerships among all parties regarding strategies for successful clinical trial development and execution. This article discusses the rationale, structure, and function of the TDC, the status of progress toward its goals, and the insights gained to date that may be useful for other subspecialties that face similar challenges.

AB - The conduct of clinical trials in small pediatric subspecialties such as pediatric nephrology is hampered by both clinical demands on the pediatric nephrologist and the small number of appropriate patients available for such studies. The American Society of Pediatric Nephrology Therapeutics Development Committee (TDC) was established to (1) identify the various stakeholders with interests and/or expertise related to clinical trials in children with kidney disease and (2) develop more effective partnerships among all parties regarding strategies for successful clinical trial development and execution. This article discusses the rationale, structure, and function of the TDC, the status of progress toward its goals, and the insights gained to date that may be useful for other subspecialties that face similar challenges.

UR - http://www.scopus.com/inward/record.url?scp=85031758239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031758239&partnerID=8YFLogxK

U2 - 10.1038/pr.2017.180

DO - 10.1038/pr.2017.180

M3 - Review article

C2 - 28853726

AN - SCOPUS:85031758239

VL - 82

SP - 727

EP - 732

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 5

ER -